Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
New York University has sold a portion of its royalty interest in the arthritis drug Remicade to Royalty Pharma, a New York City-based firm that buys revenue-producing intellectual property. NYU will receive $650 million in cash plus additional payments should Remicade, marketed by Johnson & Johnson, exceed certain sales milestones. NYU retains the portion of the royalty payable to the university researchers who developed the monoclonal antibody. Royalty Pharma also has royalty interests in drugs such as Abbott Laboratories' Humira, Amgen's Neupogen, and Genentech's Rituxan.
This article has been sent to the following recipient: